Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

5.95
-0.2300-3.72%
Post-market: 5.950.00000.00%16:10 EDT
Volume:1.39M
Turnover:8.40M
Market Cap:875.83M
PE:-10.15
High:6.27
Open:6.24
Low:5.90
Close:6.18
52wk High:6.60
52wk Low:1.74
Shares:147.20M
Float Shares:110.00M
Volume Ratio:0.95
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:7.03
PE(LYR):-11.23

Loading ...

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

GlobeNewswire
·
Apr 28

Aclaris Therapeutics announces upcoming annual shareholder meeting

Reuters
·
Apr 23

Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum

TIPRANKS
·
Apr 17

Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target

MT Newswires Live
·
Apr 16

Aclaris Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $10

THOMSON REUTERS
·
Apr 16

Aclaris Therapeutics Initiated at Outperform by Oppenheimer

Dow Jones
·
Apr 16

U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services

Reuters
·
Apr 16

Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO

Reuters
·
Apr 10

Aclaris CEO to join fireside chat at H.C. Wainwright skin disease conference

Reuters
·
Apr 08

Aclaris Therapeutics Price Target Maintained With a $8.00/Share by Wedbush

Dow Jones
·
Mar 31

Aclaris Therapeutics Phase 2a week 12 EASI improvement climbs 77% on ATI-2138 10 mg BID; BSA improvement grows 70%

Reuters
·
Mar 27

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

GlobeNewswire
·
Mar 27

Aclaris Therapeutics to present Phase 2a ATI-2138 atopic dermatitis trial results at 2026 AAD meeting

Reuters
·
Mar 20

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 19

Aclaris Therapeutics completes enrollment of 109 patients in Phase 2 bosakitug trial for atopic dermatitis

Reuters
·
Mar 18

Aclaris Therapeutics Inc - Top Line Results From Phase 2 Trial Expected in Q4 2026

THOMSON REUTERS
·
Mar 18

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

GlobeNewswire
·
Mar 18

Aclaris Therapeutics Raises $20 Million in Equity Financing

TIPRANKS
·
Mar 12

Aclaris Therapeutics sells 5.7 million shares for USD 20 million

Reuters
·
Mar 12